SCHEMBL15564656

SCHEMBL15564656

CS(=O)(=O)N1Cc2cccc(CO)c2C1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
XIAP P98170 1/20 0.41
TIPARP Q7Z3E1 1/20 0.40
MAPK1 P28482 1/20 0.39
ALDH1A1 P00352 2/20 0.38
HTR6 P50406 5/20 0.37
DRD3 P35462 4/20 0.37
LIPG Q9Y5X9 1/20 0.37
DRD2 P14416 2/20 0.37
ESR1 P03372 1/20 0.37
ESR2 Q92731 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HTT P42858 2/20 0.36
TSHR P16473 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALOX15 P16050 1/20 0.35
PRMT5 O14744 1/20 0.35
WDR77 Q9BQA1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14904831 0.87 ESR1 (0.47) TIPARPMAPK1LIPGESR1ESR2
SCHEMBL20424466 0.84 ALDH1A1 (0.43) XIAPMAPK1ALDH1A1HTR6DRD3
SCHEMBL20424706 0.77 XIAP (0.38) XIAPMAPK1ALDH1A1HTR6DRD3
SCHEMBL20436365 0.77 ALDH1A1 (0.49) MAPK1ALDH1A1HTR6DRD3DRD2
SCHEMBL520028 0.76 AKR1C3 (0.44) ALDH1A1HTR6DRD3DRD2ESR1
SCHEMBL25734243 0.75 ALDH1A1 (0.43) ALDH1A1HTR6DRD3HTTTSHR
SCHEMBL16417641 0.74 ESR1 (0.46) HTR6DRD3LIPGDRD2ESR1
SCHEMBL19608843 0.74 ESR1 (0.46) HTR6DRD3DRD2ESR1ESR2
SCHEMBL1266336 0.73 ESR1 (0.49) MAPK1ALDH1A1ESR1ESR2TSHR
SCHEMBL23612481 0.73 HTR6 (0.38) XIAPALDH1A1HTR6DRD3LIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9394263-B2 Substituted hetero-azepinones F. HOFFMANN-LA ROCHE AG (CH) 2016-07-19 US disclosed
US-9394263-B2 Substituted hetero-azepinones F. HOFFMANN-LA ROCHE AG (CH) 2016-07-19 US disclosed
US-9394263-B2 Substituted hetero-azepinones F. HOFFMANN-LA ROCHE AG (CH) 2016-07-19 US disclosed
US-20150361059-A1 SUBSTITUTED HETERO-AZEPINONES HOFFMAN-LA ROCHE INC. (US) 2015-12-17 US disclosed
US-20150361059-A1 SUBSTITUTED HETERO-AZEPINONES HOFFMAN-LA ROCHE INC. (US) 2015-12-17 US disclosed
US-20150361059-A1 SUBSTITUTED HETERO-AZEPINONES HOFFMAN-LA ROCHE INC. (US) 2015-12-17 US disclosed
EP-2882725-A1 SUBSTITUTED HETERO-AZEPINONES F. Hoffmann-La Roche AG (CH) 2015-06-17 EP disclosed
WO-2014023708-A1 SUBSTITUTED HETERO-AZEPINONES F. HOFFMANN-LA ROCHE AG (CH) 2014-02-13 WO disclosed
WO-2014023708-A1 SUBSTITUTED HETERO-AZEPINONES F. HOFFMANN-LA ROCHE AG (CH) 2014-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150361059-A1 SUBSTITUTED HETERO-AZEPINONES CCNY, CCNE1, CCND3 XIAP 1935/4885TIPARP 952/4885MAPK1 4251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.